[1] |
Faria SC, Ganesan K, Mwangi I, et al. MR imaging of liver fibrosis: current state of the art [J]. Radiographics, 2009, 29(6): 1615-1636.
|
[2] |
Van Beers BE, Pastor CM, Hussain HK. Primovist, eovist: what to expect? [J]. J Hepatol, 2012, 57(2): 421-429.
|
[3] |
Ding Y, Rao SX, Meng T, et al. Usefulness of T1 mapping on Gd-EOB-DTPA-enhanced MR imaging in assessment of non-alcoholic fatty liver disease [J]. Eur Radiol, 2014, 24(4): 959-966.
|
[4] |
Feier D, Balassy C, Bastati N, et al. Liver Fibrosis: Histopathologic and biochemical influences on diagnostic efficacy of hepatobiliary contrast-enhanced MR imaging in staging [J]. Radiology, 2013, 269(2): 459-467.
|
[5] |
徐佳,王萱,金征宇. 增强MRI定量评价肝纤维化及肝功能的研究进展 [J]. 中华放射学杂志, 2016, 50(12): 994-996.
|
[6] |
赵广强,翁苓苓,陈义磊, 等. 弥散加权成像与弥散张量成像评价肝纤维化的实验研究 [J]. 医学影像学杂志, 2016, 26(1): 99-104.
|
[7] |
Bakan AA, Inci E, Bakan S, et al. Utility of diffusion-weighted imaging in the evaluation of liver fibrosis [J]. Eur Radiol, 2012, 22(3): 682-687.
|
[8] |
Lagadec M, Doblas S, Giraudeau C, et al. Advanced fibrosis: correlation between pharmacokinetic parameters at dynamic gadoxetate-enhanced MR imaging and hepatocyte organic anion transporter expression in rat liver [J]. Radiology, 2015, 274(2): 379-386.
|
[9] |
Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C [J]. Hepatology, 1996, 24(2): 289-293.
|
[10] |
Delong ER, Delong DM, Clarkepearson DI. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach [J]. Biometrics, 1988, 44(3): 837-845.
|
[11] |
金博. 肝硬化是可以逆转的吗? [J/CD]. 中华临床医师杂志(电子版), 2015, 9(10): 5-9.
|
[12] |
Nishie A, Asayama Y, Ishigami K, et al. MR prediction of liver fibrosis using a liver-specific contrast agent: Superparamagnetic iron oxide versus Gd-EOB-DTPA [J]. J Magn Reson Imaging, 2012, 36(3): 664-671.
|
[13] |
陈永鹏,汪艳,侯金林. 肝纤维化/肝硬化的动态变化及其诊断进展 [J]. 中华肝脏病杂志, 2015, 23(4): 244-246.
|
[14] |
Banerjee R, Pavlides M, Tunnicliffe EM, et al. Multiparametric magnetic resonance for the non-invasive diagnosis of liver disease [J]. J Hepatol, 2014, 60(1): 69-77.
|
[15] |
Ding Y, Rao SX, Zhu T, et al. Liver fibrosis staging using T1 mapping on gadoxetic acid-enhanced MRI compared with DW imaging [J]. Clin Radiol, 2015, 70(10): 1096-1103.
|
[16] |
Yang L, Ding Y, Rao S, et al. Staging liver fibrosis in chronic hepatitis B with T-1 relaxation time index on gadoxetic acid-enhanced MRI: Comparison with aspartate aminotransferase-to-platelet ratio index and FIB-4 [J]. J Magn Reson Imaging, 2017, 45(4): 1186-1194.
|
[17] |
Besa C, Bane O, Jajamovich G, et al. 3D T1 relaxometry pre and post gadoxetic acid injection for the assessment of liver cirrhosis and liver function [J]. Magn Reson Imaging, 2015, 33(9): 1075-1082.
|
[18] |
Shenoy-Bhangle A, Baliyan V, Kordbacheh H, et al. Diffusion weighted magnetic resonance imaging of liver: Principles, clinical applications and recent updates [J]. World J Hepatol, 2017, 9(26): 1081-1091.
|
[19] |
Yoon JH, Lee JM, Baek JH, et al. Evaluation of hepatic fibrosis using intravoxel incoherent motion in diffusion-weighted liver MRI [J]. J Comput Assist Tomogr, 2014, 38(1): 110-116.
|